Jul 07,2026 Arnatar Therapeutics Receives China NMPA Clearance to Initiate First-in-Human Study of ART5, a First-in-Class Up-Regulating ASO Designed to Restore Polycystin-1 for the Treatment of ADPKD read more >>
Jun 02,2026 Subtle Medical Secures $33 Million in Growth Capital Led by Morgan Stanley Expansion Capital and Appoints Industry Veteran Ohad Arazi as CEO read more >>
Jun 01,2026 Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TMEM175 Agonists for Parkinson’s Disease read more >>
May 27,2026 Subtle Medical Receives FDA Clearance for SubtleHD™(PET), Next-Generation AI-Powered Image Acceleration and Enhancement Software read more >>
May 11,2026 Lysoway Therapeutics Announces Phase I Dosing of LW-1017, the First TRPML1 Agonist to Enter Clinical Development read more >>
Feb 05,2026 Galaxy Brain Scientific’s Technology Enables Landmark Parkinson’s Study Published in Nature, Redefining Disease Mechanism read more >>
Jan 05,2026 Lysoway Therapeutics Announces Phase I Readiness of Brain-Penetrant TRPML1 Agonist LW-1017 and Nomination of a TMEM175 Development Candidate read more >>